Vaccine candidates for hantavirus remain in early preclinical or Phase I/II stages as of September 2026, with no candidates advancing to pivotal efficacy trials or regulatory review that could enable approval this year. Promising mRNA platforms, including single-dose formulations showing full protection in hamster models against Andes virus and collaborative work by Moderna and Korea University, have demonstrated immunogenicity in rodents but face standard multi-year timelines for human testing, manufacturing scale-up, and safety data required by agencies like the FDA. Recent attention from the resolved MV Hondius outbreak has not accelerated late-stage progress, consistent with the market-implied 95.5% probability of no vaccine in 2026. A major funding surge or emergency authorization could theoretically shift timelines, though current conditions make that improbable.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日Hantavirus vaccine in 2026?
$135,595 Vol.
$135,595 Vol.
$135,595 Vol.
$135,595 Vol.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
マーケット開始日: May 4, 2026, 10:39 AM ET
リゾルバー
0x65070BE91...The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
リゾルバー
0x65070BE91...Vaccine candidates for hantavirus remain in early preclinical or Phase I/II stages as of September 2026, with no candidates advancing to pivotal efficacy trials or regulatory review that could enable approval this year. Promising mRNA platforms, including single-dose formulations showing full protection in hamster models against Andes virus and collaborative work by Moderna and Korea University, have demonstrated immunogenicity in rodents but face standard multi-year timelines for human testing, manufacturing scale-up, and safety data required by agencies like the FDA. Recent attention from the resolved MV Hondius outbreak has not accelerated late-stage progress, consistent with the market-implied 95.5% probability of no vaccine in 2026. A major funding surge or emergency authorization could theoretically shift timelines, though current conditions make that improbable.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日



外部リンクに注意してください。
外部リンクに注意してください。
よくある質問